{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=9", "query": { "condition": "Follicular Neoplasm", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 1364, "total_pages": 137, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Neoplasm&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T12:27:04.644Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02290951", "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Odronextamab multiple dose levels", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2015-01-09", "completion_date": "2025-08-21", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 10, "location_summary": "Orange, California • Stanford, California • Tampa, Florida + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02290951" }, { "nct_id": "NCT00004105", "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "estramustine phosphate sodium", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004105" }, { "nct_id": "NCT01154777", "title": "Collaborative Study Of Neurofeedback Training Of 6-18 Year Olds With Autism", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autism" ], "interventions": [ { "name": "Neurofeedback training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Institute for Personal Excellence, P.A.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Years to 18 Years" }, "enrollment_count": 30, "start_date": "2011-07", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2010-10-05", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 2, "location_summary": "Raleigh, North Carolina", "locations": [ { "city": "Raleigh", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154777" }, { "nct_id": "NCT01116154", "title": "Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-Cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-05", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2010-12-09", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01116154" }, { "nct_id": "NCT01831466", "title": "Tofacitinib Ointment For Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis Vulgaris", "Psoriasis" ], "interventions": [ { "name": "tofacitinib ointment 20 mg/g", "type": "DRUG" }, { "name": "tofacitinib ointment 10 mg/g", "type": "DRUG" }, { "name": "placebo ointment (vehicle)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 476, "start_date": "2013-05", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-11-25", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 29, "location_summary": "Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01831466" }, { "nct_id": "NCT00003572", "title": "Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "peripheral blood lymphocyte therapy", "type": "BIOLOGICAL" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "1998-08", "completion_date": "2002-04", "has_results": false, "last_update_posted_date": "2014-05-02", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003572" }, { "nct_id": "NCT00053157", "title": "Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "5 Years to 60 Years" }, "enrollment_count": 10, "start_date": "2002-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053157" }, { "nct_id": "NCT03037645", "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Lymphoplasmacytoid Lymphoma", "Mantle-Cell Lymphoma", "Waldenstrom Macroglobulinemia", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "SNS-062", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sunesis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-04-28", "completion_date": "2020-08-31", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 11, "location_summary": "Orange, California • San Diego, California • Tampa, Florida + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03037645" }, { "nct_id": "NCT05637801", "title": "A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease", "Alzheimer Disease 1", "Alzheimer Disease 2", "Alzheimer Disease 3", "Alzheimer Disease, Early Onset", "Alzheimer Disease, Late Onset", "Alzheimer Disease 9", "Alzheimer Disease 4", "Alzheimer Disease 7", "Alzheimer Disease 17", "Alzheimer's Dementia Late Onset", "Alzheimer Disease 5", "Alzheimer Disease 6", "Alzheimer Disease 8", "Alzheimer Disease 10", "Alzheimer Disease 11", "Alzheimer Disease 12", "Alzheimer Disease 13", "Alzheimer Disease 14", "Alzheimer Disease 15", "Alzheimer Disease 16", "Alzheimer Disease 18", "Alzheimer Disease 19", "Dementia", "Dementia Alzheimers", "Dementia, Mild", "Dementia of Alzheimer Type", "Dementia Moderate", "Dementia Senile", "Mild Cognitive Impairment", "Mild Dementia", "MCI", "Cognitive Impairment", "Cognitive Decline", "Cognitive Impairment, Mild" ], "interventions": [ { "name": "Spectris™ AD - Active", "type": "DEVICE" }, { "name": "Spectris™ AD - Sham", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cognito Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 673, "start_date": "2022-12-13", "completion_date": "2026-08-17", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 68, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05637801" }, { "nct_id": "NCT00100737", "title": "Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "interleukin-2", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chiron Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2006-02-06", "last_synced_at": "2026-10-23T12:27:04.644Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100737" } ] }